1124 related articles for article (PubMed ID: 15227622)
1. Modified vaccinia Ankara: potential as an alternative smallpox vaccine.
McCurdy LH; Larkin BD; Martin JE; Graham BS
Clin Infect Dis; 2004 Jun; 38(12):1749-53. PubMed ID: 15227622
[TBL] [Abstract][Full Text] [Related]
2. Enhanced immunogenicity and protective effect conferred by vaccination with combinations of modified vaccinia virus Ankara and licensed smallpox vaccine Dryvax in a mouse model.
Meseda CA; Garcia AD; Kumar A; Mayer AE; Manischewitz J; King LR; Golding H; Merchlinsky M; Weir JP
Virology; 2005 Sep; 339(2):164-75. PubMed ID: 15993917
[TBL] [Abstract][Full Text] [Related]
3. Comparative efficacy of modified vaccinia Ankara (MVA) as a potential replacement smallpox vaccine.
Phelps AL; Gates AJ; Hillier M; Eastaugh L; Ulaeto DO
Vaccine; 2007 Jan; 25(1):34-42. PubMed ID: 16950548
[TBL] [Abstract][Full Text] [Related]
4. Postexposure immunization with modified vaccinia virus Ankara or conventional Lister vaccine provides solid protection in a murine model of human smallpox.
Paran N; Suezer Y; Lustig S; Israely T; Schwantes A; Melamed S; Katz L; Preuss T; Hanschmann KM; Kalinke U; Erez N; Levin R; Velan B; Löwer J; Shafferman A; Sutter G
J Infect Dis; 2009 Jan; 199(1):39-48. PubMed ID: 19012492
[TBL] [Abstract][Full Text] [Related]
5. IMVAMUNE, an attenuated modified vaccinia Ankara virus vaccine for smallpox infection.
Jones T
Curr Opin Mol Ther; 2008 Aug; 10(4):407-17. PubMed ID: 18683106
[TBL] [Abstract][Full Text] [Related]
6. Substitution of vaccinia virus Elstree by modified vaccinia virus Ankara to test the virucidal efficacy of chemical disinfectants.
Hartnack S; Essbauer S; Truyen U
Zoonoses Public Health; 2008; 55(2):99-105. PubMed ID: 18234028
[TBL] [Abstract][Full Text] [Related]
7. The nonreplicating smallpox candidate vaccines defective vaccinia Lister (dVV-L) and modified vaccinia Ankara (MVA) elicit robust long-term protection.
Coulibaly S; Brühl P; Mayrhofer J; Schmid K; Gerencer M; Falkner FG
Virology; 2005 Oct; 341(1):91-101. PubMed ID: 16061267
[TBL] [Abstract][Full Text] [Related]
8. New generation smallpox vaccines: a review of preclinical and clinical data.
Artenstein AW
Rev Med Virol; 2008; 18(4):217-31. PubMed ID: 18283712
[TBL] [Abstract][Full Text] [Related]
9. Clinical development of Modified Vaccinia virus Ankara vaccines.
Gilbert SC
Vaccine; 2013 Sep; 31(39):4241-6. PubMed ID: 23523410
[TBL] [Abstract][Full Text] [Related]
10. Phase 3 Efficacy Trial of Modified Vaccinia Ankara as a Vaccine against Smallpox.
Pittman PR; Hahn M; Lee HS; Koca C; Samy N; Schmidt D; Hornung J; Weidenthaler H; Heery CR; Meyer TPH; Silbernagl G; Maclennan J; Chaplin P
N Engl J Med; 2019 Nov; 381(20):1897-1908. PubMed ID: 31722150
[TBL] [Abstract][Full Text] [Related]
11. [MVA vaccination against smallpox: clinical tests with an attenuated live vaccinia virus strain (MVA) (author's transl)].
Stickl H; Hochstein-Mintzel V; Mayr A; Huber HC; Schäfer H; Holzner A
Dtsch Med Wochenschr; 1974 Nov; 99(47):2386-92. PubMed ID: 4426258
[No Abstract] [Full Text] [Related]
12. Safety and immunogenicity of IMVAMUNE, a promising candidate as a third generation smallpox vaccine.
Vollmar J; Arndtz N; Eckl KM; Thomsen T; Petzold B; Mateo L; Schlereth B; Handley A; King L; Hülsemann V; Tzatzaris M; Merkl K; Wulff N; Chaplin P
Vaccine; 2006 Mar; 24(12):2065-70. PubMed ID: 16337719
[TBL] [Abstract][Full Text] [Related]
13. The new ACAM2000 vaccine and other therapies to control orthopoxvirus outbreaks and bioterror attacks.
Handley L; Buller RM; Frey SE; Bellone C; Parker S
Expert Rev Vaccines; 2009 Jul; 8(7):841-50. PubMed ID: 19538111
[TBL] [Abstract][Full Text] [Related]
14. Bioterrorism. Smallpox vaccinations: how much protection remains?
Cohen J
Science; 2001 Nov; 294(5544):985. PubMed ID: 11691969
[No Abstract] [Full Text] [Related]
15. [Our experiences with the 2-stage method of vaccination against smallpox (MVA virus pre-vaccination)].
Rudkowski Z; Remion J; Saraczyńska E
Pediatr Pol; 1976 May; 51(5):497-503. PubMed ID: 1272640
[No Abstract] [Full Text] [Related]
16. Oral immunization against smallpox.
Hochstein-Mintzel V; Stickl H; Huber HC
Dev Biol Stand; 1976; 33():260-6. PubMed ID: 182585
[TBL] [Abstract][Full Text] [Related]
17. Protection induced in mice against a lethal orthopox virus by the Lister strain of vaccinia virus and modified vaccinia virus Ankara (MVA).
Abdalrhman I; Gurt I; Katz E
Vaccine; 2006 May; 24(19):4152-60. PubMed ID: 16603280
[TBL] [Abstract][Full Text] [Related]
18. Determination of immunity to vaccinia virus by using diluted inactivated vaccinia vaccine solution for skin testing.
Somekh E; Smetana Z; Tanay A; Dalal I; Babai I; Mendelson E
Vaccine; 2004 Dec; 23(3):321-4. PubMed ID: 15530675
[TBL] [Abstract][Full Text] [Related]
19. [Development of a numerically additive combined vaccine against tetanus and smallpox].
Mayr A; Baljer G; Wagner C; Sailer J
Zentralbl Bakteriol Mikrobiol Hyg A; 1985 Apr; 259(2):206-18. PubMed ID: 2990123
[TBL] [Abstract][Full Text] [Related]
20. Short- and long-term immunogenicity and protection induced by non-replicating smallpox vaccine candidates in mice and comparison with the traditional 1st generation vaccine.
Ferrier-Rembert A; Drillien R; Tournier JN; Garin D; Crance JM
Vaccine; 2008 Mar; 26(14):1794-804. PubMed ID: 18336966
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
